204 related articles for article (PubMed ID: 38443545)
1. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer.
McDevitt T; Durkie M; Arnold N; Burghel GJ; Butler S; Claes KBM; Logan P; Robinson R; Sheils K; Wolstenholme N; Hanson H; Turnbull C; Hume S
Eur J Hum Genet; 2024 May; 32(5):479-488. PubMed ID: 38443545
[TBL] [Abstract][Full Text] [Related]
2. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
Hessock M; Brewer T; Hutson S; Anderson J
Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
[TBL] [Abstract][Full Text] [Related]
3. Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
Petelin L; James PA; Trainer AH
Intern Med J; 2018 Oct; 48(10):1269-1272. PubMed ID: 30288903
[TBL] [Abstract][Full Text] [Related]
4. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
[TBL] [Abstract][Full Text] [Related]
5. Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
Bellcross CA
Obstet Gynecol Clin North Am; 2022 Mar; 49(1):117-147. PubMed ID: 35168766
[TBL] [Abstract][Full Text] [Related]
6. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
Marmolejo DH; Wong MYZ; Bajalica-Lagercrantz S; Tischkowitz M; Balmaña J;
Eur J Med Genet; 2021 Dec; 64(12):104350. PubMed ID: 34606975
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
Clin Genet; 2022 Mar; 101(3):324-334. PubMed ID: 34927729
[TBL] [Abstract][Full Text] [Related]
8. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
9. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
Meaney-Delman D; Bellcross CA
Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
[TBL] [Abstract][Full Text] [Related]
10. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
[No Abstract] [Full Text] [Related]
11. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract][Full Text] [Related]
12. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract][Full Text] [Related]
13. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
14. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review.
Afaya A; Kim SW; Park HS; Lim MC; Jung MS; Nam EJ; Park JS; Jeong J; Ryu JM; Kim J; Kim J; Kim M; Jin J; Han J; Kim SY; Park SY; Katapodi MC; Kim S;
Fam Cancer; 2024 Jun; 23(2):121-132. PubMed ID: 38662264
[TBL] [Abstract][Full Text] [Related]
15. HBOC multi-gene panel testing: comparison of two sequencing centers.
Schroeder C; Faust U; Sturm M; Hackmann K; Grundmann K; Harmuth F; Bosse K; Kehrer M; Benkert T; Klink B; Mackenroth L; Betcheva-Krajcir E; Wimberger P; Kast K; Heilig M; Nguyen HP; Riess O; Schröck E; Bauer P; Rump A
Breast Cancer Res Treat; 2015 Jul; 152(1):129-136. PubMed ID: 26022348
[TBL] [Abstract][Full Text] [Related]
16. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
Macquere P; Orazio S; Bonnet F; Jones N; Bubien V; Chiron J; Lafon D; Barouk-Simonet E; Tinat J; Venat-Bouvet L; Gesta P; Longy M; Sevenet N
J Hum Genet; 2022 Jun; 67(6):339-345. PubMed ID: 35017683
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
18. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
[TBL] [Abstract][Full Text] [Related]
19. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Shao D; Cheng S; Guo F; Zhu C; Yuan Y; Hu K; Wang Z; Meng X; Jin X; Xiong Y; Chai X; Li H; Zhang Y; Zhang H; Liu J; Ye M
Cancer Sci; 2020 Feb; 111(2):647-657. PubMed ID: 31742824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
